earnings
confidence high
sentiment positive
materiality 0.70
Interpace Q1 revenue $11.5M (+13% YoY); guides FY2025 ~$38M
INTERPACE BIOSCIENCES, INC.
2025-Q1 EPS reported
$0.06
revenue$11,515,000
- Net revenue $11.5M (+13% YoY); income from continuing ops $1.8M vs $0.8M.
- Thyroid revenue $8.0M (+19% YoY) to record; test volume up 16%.
- Cash collections $11.3M (+10% YoY) to record; adjusted EBITDA $2.1M vs $1.2M.
- Initiates FY2025 revenue guidance of approx. $38M despite PancraGEN loss after May 2.
- Gross profit margin improved to 64% from 62%.